Clinical trial

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

NCT03287310

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-10-17

PhasePHASE1

Study timeline

Study start (actual)2017-10-17Date precision: day

Registry last updated2021-03-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

GSK3511294DRUG

PlaceboDRUG

Salbutamol/albuterolDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

LondonUnited Kingdom1 BerlinGermany1 ManchesterUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03287310 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.